Peer-reviewedCC BY-NC-ND 4.0Nature Communications
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
Related
- A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation
- Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report
- Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor–Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma
- Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris
- Efficacy and Safety of Datopotamab Deruxtecan From a Single-Institution Experience in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody-Drug Conjugates.
BibTeX
@article{giacomo2026conformationselective,
title = {{The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial}},
author = {Anna Maria Di Giacomo and Matteo Simonelli and Agnese Losurdo and Pavlina Spiliopoulou and Vincenzo D’Alonzo and Giovanni Amato and Monica Valente and Hugo Barcenilla and Anette Johnsson and Laura Gonzalez and Ziyang Tan and Lakshmikanth Tadepally and Petter Brodin and Michael Lahn and Giusy Di Conza and Rebeca Zorrilla and Lars van der Veen and Alessio Bevilacqua and Paramjit Kaur and Tracey Hammett and Marco Durini and Andrea Corsi and Nikhil Sindhwani and Mariaelena Occhipinti and Robert Snijder and Ayad Abdul-Ahad and Aniko Meijer and Umberto Postiglione and Gregory Price and Gillian Hopton and Emily Wood and Vincent Vuaroqueaux and Anne-Lise Peille and Jill Graham and Ming Poi and David Spetzler and Carmelo Carlo-Stella and Armando Santoro and Thomas R. Jeffry Evans and Michele Maio},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/s41467-026-77358-7},
url = {https://www.nature.com/articles/s41467-026-77358-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
AU - Anna Maria Di Giacomo
AU - Matteo Simonelli
AU - Agnese Losurdo
AU - Pavlina Spiliopoulou
AU - Vincenzo D’Alonzo
AU - Giovanni Amato
AU - Monica Valente
AU - Hugo Barcenilla
AU - Anette Johnsson
AU - Laura Gonzalez
AU - Ziyang Tan
AU - Lakshmikanth Tadepally
AU - Petter Brodin
AU - Michael Lahn
AU - Giusy Di Conza
AU - Rebeca Zorrilla
AU - Lars van der Veen
AU - Alessio Bevilacqua
AU - Paramjit Kaur
AU - Tracey Hammett
AU - Marco Durini
AU - Andrea Corsi
AU - Nikhil Sindhwani
AU - Mariaelena Occhipinti
AU - Robert Snijder
AU - Ayad Abdul-Ahad
AU - Aniko Meijer
AU - Umberto Postiglione
AU - Gregory Price
AU - Gillian Hopton
AU - Emily Wood
AU - Vincent Vuaroqueaux
AU - Anne-Lise Peille
AU - Jill Graham
AU - Ming Poi
AU - David Spetzler
AU - Carmelo Carlo-Stella
AU - Armando Santoro
AU - Thomas R. Jeffry Evans
AU - Michele Maio
PY - 2026
DA - 2026/10/09
JO - Nature Communications
DO - 10.1038/s41467-026-77358-7
UR - https://www.nature.com/articles/s41467-026-77358-7
SN - 2041-1723
ER -